NYSE:NVST

Envista Competitors

$45.48
+0.64 (+1.43 %)
(As of 05/7/2021 04:15 PM ET)
Add
Compare
Today's Range
$44.70
$46.52
50-Day Range
$39.55
$44.15
52-Week Range
$14.73
$46.52
Volume3.16 million shs
Average Volume2.17 million shs
Market Capitalization$7.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta2

Competitors

Envista (NYSE:NVST) Vs. BGNE, RMD, LH, SGEN, GMAB, and WST

Should you be buying NVST stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Envista, including BeiGene (BGNE), ResMed (RMD), Laboratory Co. of America (LH), Seagen (SGEN), Genmab A/S (GMAB), and West Pharmaceutical Services (WST).

BeiGene (NASDAQ:BGNE) and Envista (NYSE:NVST) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for BeiGene and Envista, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene21602.44
Envista03402.57

BeiGene currently has a consensus price target of $319.3750, suggesting a potential upside of 2.69%. Envista has a consensus price target of $38.50, suggesting a potential downside of 15.35%. Given BeiGene's higher probable upside, equities analysts clearly believe BeiGene is more favorable than Envista.

Volatility and Risk

BeiGene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Envista has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500.

Profitability

This table compares BeiGene and Envista's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
Envista-0.84%4.30%2.36%

Insider and Institutional Ownership

60.7% of BeiGene shares are held by institutional investors. 9.0% of BeiGene shares are held by insiders. Comparatively, 0.6% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BeiGene and Envista's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million66.81$-948,630,000.00($15.80)-19.74
Envista$2.75 billion2.66$217.60 million$1.7925.41

Envista has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Summary

Envista beats BeiGene on 8 of the 14 factors compared between the two stocks.

Envista (NYSE:NVST) and ResMed (NYSE:RMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Envista and ResMed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Envista03402.57
ResMed06402.40

Envista currently has a consensus price target of $38.50, suggesting a potential downside of 15.35%. ResMed has a consensus price target of $196.00, suggesting a potential upside of 0.40%. Given ResMed's higher probable upside, analysts plainly believe ResMed is more favorable than Envista.

Volatility & Risk

Envista has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.

Profitability

This table compares Envista and ResMed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Envista-0.84%4.30%2.36%
ResMed22.45%30.64%16.43%

Institutional and Insider Ownership

68.6% of ResMed shares are held by institutional investors. 0.6% of Envista shares are held by insiders. Comparatively, 1.3% of ResMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Envista and ResMed's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.75 billion2.66$217.60 million$1.7925.41
ResMed$2.96 billion9.60$621.67 million$4.7641.00

ResMed has higher revenue and earnings than Envista. Envista is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Summary

ResMed beats Envista on 11 of the 13 factors compared between the two stocks.

Envista (NYSE:NVST) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Envista and Laboratory Co. of America, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Envista03402.57
Laboratory Co. of America001303.00

Envista currently has a consensus price target of $38.50, suggesting a potential downside of 15.35%. Laboratory Co. of America has a consensus price target of $263.0714, suggesting a potential downside of 5.42%. Given Laboratory Co. of America's stronger consensus rating and higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Envista.

Volatility & Risk

Envista has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Profitability

This table compares Envista and Laboratory Co. of America's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Envista-0.84%4.30%2.36%
Laboratory Co. of America6.79%21.05%8.83%

Institutional and Insider Ownership

89.3% of Laboratory Co. of America shares are held by institutional investors. 0.6% of Envista shares are held by insiders. Comparatively, 0.7% of Laboratory Co. of America shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Envista and Laboratory Co. of America's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.75 billion2.66$217.60 million$1.7925.41
Laboratory Co. of America$11.55 billion2.35$823.80 million$11.3224.57

Laboratory Co. of America has higher revenue and earnings than Envista. Laboratory Co. of America is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Summary

Laboratory Co. of America beats Envista on 12 of the 14 factors compared between the two stocks.

Envista (NYSE:NVST) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Envista and Seagen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Envista03402.57
Seagen06912.69

Envista currently has a consensus price target of $38.50, suggesting a potential downside of 15.35%. Seagen has a consensus price target of $188.9231, suggesting a potential upside of 35.44%. Given Seagen's stronger consensus rating and higher probable upside, analysts plainly believe Seagen is more favorable than Envista.

Volatility & Risk

Envista has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Profitability

This table compares Envista and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Envista-0.84%4.30%2.36%
Seagen25.34%20.46%16.67%

Institutional and Insider Ownership

87.2% of Seagen shares are held by institutional investors. 0.6% of Envista shares are held by insiders. Comparatively, 31.1% of Seagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Envista and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.75 billion2.66$217.60 million$1.7925.41
Seagen$916.71 million27.61$-158,650,000.00($1.33)-104.88

Envista has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Envista on 11 of the 15 factors compared between the two stocks.

Envista (NYSE:NVST) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Volatility & Risk

Envista has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.

Profitability

This table compares Envista and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Envista-0.84%4.30%2.36%
Genmab A/S50.99%34.40%30.67%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Envista and Genmab A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Envista03402.57
Genmab A/S24902.47

Envista currently has a consensus price target of $38.50, suggesting a potential downside of 15.35%. Genmab A/S has a consensus price target of $41.5714, suggesting a potential upside of 10.92%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Envista.

Institutional and Insider Ownership

6.2% of Genmab A/S shares are held by institutional investors. 0.6% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Envista and Genmab A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.75 billion2.66$217.60 million$1.7925.41
Genmab A/S$804.57 million30.49$324.68 million$0.5173.33

Genmab A/S has lower revenue, but higher earnings than Envista. Envista is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Genmab A/S beats Envista on 9 of the 14 factors compared between the two stocks.

Envista (NYSE:NVST) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Envista has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Profitability

This table compares Envista and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Envista-0.84%4.30%2.36%
West Pharmaceutical Services14.69%19.01%12.78%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Envista and West Pharmaceutical Services, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Envista03402.57
West Pharmaceutical Services01202.67

Envista presently has a consensus target price of $38.50, suggesting a potential downside of 15.35%. West Pharmaceutical Services has a consensus target price of $310.00, suggesting a potential downside of 7.20%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Envista.

Institutional & Insider Ownership

92.6% of West Pharmaceutical Services shares are owned by institutional investors. 0.6% of Envista shares are owned by company insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Envista and West Pharmaceutical Services' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.75 billion2.66$217.60 million$1.7925.41
West Pharmaceutical Services$1.84 billion13.39$241.70 million$3.24102.99

West Pharmaceutical Services has lower revenue, but higher earnings than Envista. Envista is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Summary

West Pharmaceutical Services beats Envista on 11 of the 14 factors compared between the two stocks.

Ad All Marijuana Stocks
Attention: Late Cannabis Investors - Check This Out Now!
Experts say this technology could change everything for the retail cannabis market. So, if you were late last time, check this out now!

Envista Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BeiGene logo
BGNE
BeiGene
1.1$311.97+0.7%$28.79 billion$428.21 million-15.44Earnings Announcement
Insider Selling
News Coverage
Gap Up
ResMed logo
RMD
ResMed
1.5$195.16+1.1%$28.10 billion$2.96 billion41.88
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.4$278.14+0.0%$27.15 billion$11.55 billion32.38Insider Selling
Analyst Revision
Seagen logo
SGEN
Seagen
1.7$139.49+2.5%$25.31 billion$916.71 million54.92
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.40+0.5%$24.41 billion$804.57 million28.99Earnings Announcement
Analyst Revision
News Coverage
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$333.68+1.3%$24.32 billion$1.84 billion88.04Dividend Announcement
AmerisourceBergen logo
ABC
AmerisourceBergen
1.5$120.86+2.7%$24.08 billion$189.89 billion-7.20Earnings Announcement
Dividend Announcement
Analyst Report
Teladoc Health logo
TDOC
Teladoc Health
1.7$151.04+0.6%$23.44 billion$553.31 million-105.62Analyst Report
Insider Selling
Cerner logo
CERN
Cerner
2.6$76.68+2.0%$23.18 billion$5.69 billion29.95Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$39.40+1.5%$22.72 billion$19.58 billion15.63Earnings Announcement
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.8$87.93+2.2%$20.14 billion$1.30 billion24.02Earnings Announcement
The Cooper Companies logo
COO
The Cooper Companies
1.9$404.34+0.3%$19.93 billion$2.43 billion84.06Analyst Report
NovoCure logo
NVCR
NovoCure
1.6$192.45+0.6%$19.90 billion$351.32 million1,012.95Insider Selling
Smith & Nephew logo
SNN
Smith & Nephew
1.9$43.99+0.9%$19.16 billion$5.14 billion21.56Analyst Report
Teleflex logo
TFX
Teleflex
2.0$412.55+1.2%$19.05 billion$2.60 billion53.10Dividend Announcement
Analyst Report
Analyst Revision
BIO.B
Bio-Rad Laboratories
0.7$631.85+0.0%$18.85 billion$2.31 billion5.41
CureVac logo
CVAC
CureVac
0.7$100.40+6.4%$18.77 billionN/A0.00Increase in Short Interest
Gap Up
Incyte logo
INCY
Incyte
1.6$82.74+0.5%$18.19 billion$2.16 billion-52.70Earnings Announcement
Analyst Report
Decrease in Short Interest
Quest Diagnostics logo
DGX
Quest Diagnostics
1.9$138.95+0.4%$18.08 billion$7.73 billion17.18Analyst Upgrade
Catalent logo
CTLT
Catalent
1.7$107.56+1.3%$18.07 billion$3.09 billion68.51Earnings Announcement
Analyst Upgrade
Avantor logo
AVTR
Avantor
2.0$31.22+0.6%$18.06 billion$6.04 billion260.17Analyst Upgrade
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$608.01+1.0%$17.97 billion$2.31 billion5.20
STERIS logo
STE
STERIS
2.1$211.50+0.6%$17.95 billion$3.03 billion42.90
Exact Sciences logo
EXAS
Exact Sciences
2.0$104.50+3.4%$17.90 billion$876.29 million-47.28Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$342.55+1.7%$16.91 billion$2.62 billion57.09Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
News Coverage
Viatris logo
VTRS
Viatris
1.7$14.08+1.1%$16.84 billionN/A0.00Upcoming Earnings
Insulet logo
PODD
Insulet
1.4$234.19+8.1%$16.76 billion$738.20 million532.26Analyst Report
News Coverage
Gap Down
Hologic logo
HOLX
Hologic
2.3$65.63+0.7%$16.70 billion$3.78 billion15.63Analyst Report
Cardinal Health logo
CAH
Cardinal Health
2.4$58.16+2.8%$16.60 billion$152.92 billion17.57Earnings Announcement
News Coverage
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07+0.0%$16.26 billion$3.17 billion60.43
PPD logo
PPD
PPD
1.7$46.10+0.1%$16.20 billion$4.03 billion307.33Analyst Report
Bio-Techne logo
TECH
Bio-Techne
1.8$423.05+2.9%$15.95 billion$738.69 million67.69Earnings Announcement
Dividend Announcement
Analyst Downgrade
News Coverage
10x Genomics logo
TXG
10x Genomics
1.8$146.36+1.3%$15.71 billion$245.89 million-108.41Earnings Announcement
Insider Selling
Unusual Options Activity
News Coverage
Gap Up
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$131.30+0.6%$15.53 billion$219.75 million-16.77Analyst Report
Molina Healthcare logo
MOH
Molina Healthcare
1.5$267.84+1.6%$15.40 billion$16.83 billion20.08Analyst Report
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$68.47+1.6%$14.70 billion$4.03 billion-297.70Earnings Announcement
Analyst Report
News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.88+5.6%$14.68 billion$3.07 billion-57.68News Coverage
Gap Up
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.77+1.1%$14.37 billion$1.70 billion17.80Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$158.14+1.6%$14.10 billion$12.98 million-52.19Upcoming Earnings
Insider Selling
GoodRx logo
GDRX
GoodRx
1.5$34.74+1.0%$13.76 billion$388.22 million0.00Upcoming Earnings
Guardant Health logo
GH
Guardant Health
1.7$135.39+0.6%$13.69 billion$214.38 million-70.88Earnings Announcement
Analyst Report
News Coverage
Gap Down
Oak Street Health logo
OSH
Oak Street Health
1.7$58.11+2.7%$13.61 billionN/A0.00Upcoming Earnings
Insider Selling
Analyst Revision
Abiomed logo
ABMD
Abiomed
1.6$296.81+0.4%$13.38 billion$840.88 million65.23
argenx logo
ARGX
argenx
1.3$263.70+2.1%$13.25 billion$78.17 million-55.75Upcoming Earnings
Universal Health Services logo
UHS
Universal Health Services
1.8$155.19+0.5%$13.21 billion$11.38 billion15.21Analyst Report
DaVita logo
DVA
DaVita
1.7$126.80+2.0%$13.20 billion$11.39 billion19.01Insider Selling
Analyst Revision
Novavax logo
NVAX
Novavax
1.6$176.00+2.0%$12.78 billion$18.66 million-33.72Upcoming Earnings
Insider Selling
Gap Up
Grifols logo
GRFS
Grifols
1.3$18.23+1.4%$12.36 billion$5.71 billion16.28Earnings Announcement
AGL
agilon health
0.0$33.49+4.2%$12.32 billionN/A0.00News Coverage
Masimo logo
MASI
Masimo
1.8$224.16+1.2%$12.18 billion$937.84 million58.22
This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.